• Tianhang Li, Zhaohui Gu, Yueling Zhang, Jie Li, Juan Du, and Yan Fu.
• Tianhang Li, Ward of Ophthalmology 2nd Department, Baoding No.1 Central Hospital, Baoing 071000, Hebei, China.
• Pak J Med Sci. 2024 Dec 1; 40 (11): 264826522648-2652.

ObjectiveTo investigate the efficacy of anti-vascular endothelial growth factor (VEGF) drugs in diabetic retinopathy (DR)-retinal microaneurysms, and its prognosis.MethodThis was a retrospectively study in which total of 120 patients with DR in Baoding No.1 Central Hospital from June 2020 to June 2022 were retrospectively analyzed. According to different treatment methods based on macular edema, they were divided into an injection group and a control group. The control group was treated routinely, while the injection group was additionally intravitreally injected with an anti-VEGF drug. The patients were followed up for one year, and the changes in the number of retinal microaneurysms, best corrected visual acuity (BCVA) and central retinal thickness (CRT) were compared between the two groups. The effect on retinal microaneurysms was analyzed.ResultAfter treatment for 12 months, the total efficacy of the injection group was 95.00%, which was higher than 80.00% of the control group (p< 0.05). After one, three, six and twelve months of treatment, both CRT and the number of retinal microaneurysms reduced in the injection group compared with those before treatment. After treatment for one, three, six and twelve months, BCVA showed increases in the injection group, but no obvious changes in the control group compared with that before treatment.ConclusionFor patients with DR complicated with macular edema, early use of anti-VEGF drugs can significantly improve the fundus lesions, reduce the CRT and number of retinal microaneurysms, and improve the BCVA of the patients, with high clinical efficacy.Copyright: © Pakistan Journal of Medical Sciences.

6 keywords...

hide…